Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ACM-012
- Development stage
- Preclinical
- Lead developer
- ACM Biolabs
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
ACM-012 is a thermostable mRNA vaccine candidate developed by ACM Biolabs for the prevention of rabies. It utilizes the company's proprietary Artificial Cell Membrane (ACM) platform, specifically the ATP (Artificial cell membrane Tunable Particle) nanoparticle delivery system. This platform is designed to encapsulate mRNA encoding rabies virus antigens, providing enhanced stability at refrigerated temperatures (2–8°C), which eliminates the need for ultra-cold chain logistics. The program is supported by funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of pandemic-ready vaccines. As of early 2026, the program is in the IND-enabling phase of development.
- Other names
- mRNA Rabies Vaccine
02
Targets
RABV-G (Rabies virus glycoprotein)
Beyond the preview
Go deeper on ACM-012.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ACM-012.